We are increasing our geopolitical coverage and a struggling healthcare stock.
We are expanding our only oil reserve and a disadvantaged medical technology company.
Jim Cramer
Eli Lilly's big investment in GLP-1, plus CRM, BBY, FL and COST earnings next week
Every weekday, the CNBC Investing Club with Jim Cramer hosts a “Morning Meeting” livestream at 10:20 a.m. ET. Here's a…
The stock market is again under attack by the Federal Reserve. Plus, the quiet return of Starbucks
Every weekday, the CNBC Investing Club with Jim Cramer publishes Homestretch, a helpful afternoon update just in time for the…
Activist's willingness to buy Abbott rival and look beyond baby formula suits
Every weekday, the CNBC Investing Club with Jim Cramer publishes Homestretch, a helpful afternoon update just in time for the…
Eli Lilly shares hit new highs after a regulatory victory in China. This is a big problem
Every weekday, the CNBC Investing Club with Jim Cramer hosts a “Morning Meeting” livestream at 10:20 a.m. ET. Here's a…
Danaher shows how holding a good company's troubled stock can pay off
Every weekday, the CNBC Investing Club with Jim Cramer publishes Homestretch, a helpful afternoon update just in time for the…
No Surprise Amazon Stock Down After Cloud CEO Shakeup
Every weekday, the CNBC Investing Club with Jim Cramer hosts a “Morning Meeting” livestream at 10:20 a.m. ET. Here's a…
Unjustified drop after GEHC results is a buying opportunity
Every weekday, the CNBC Investing Club with Jim Cramer publishes Homestretch, a helpful afternoon update just in time for the…
Eli Lilly (LLY) Says It Can Overcome the Problem of Too Much Demand for High Quality
Eli Lilly's improved guidance stole the show on Tuesday, offsetting mixed first-quarter results and sending shares up nearly 6%. The…
The promise of Eli Lilly's weight-loss drug for sleep apnea adds reasons to own it
Eli Lilly's weight-loss drug Zepbound showed promise as a treatment for sleep apnea, giving investors more confidence to continue owning…